BioSpace News Archive

eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

TELA Bio, Inc. today announced that the Company will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, 12th Annual Jefferies London Healthcare Conference

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced its participation in the fifth annual Barclays Gene Editing & Gene Therapy Summit on Monday, November 15, 2021.

Axsome Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2021.

Amarin Corporation plc (NASDAQ:AMRN) today announced that new data that add to the growing body of knowledge on VASCEPA®/VAZKEPA (icosapent ethyl), including in patients at risk for major adverse cardiovascular events, will be presented at the American Heart Association (AHA) Scientific Sessions 2021 taking place virtually from November 13 – November 15, 2021.

Campaign for Lung Cancer Awareness Month aims to empower Canadians to be the MVP in the fight against lung cancer

Bio-Techne Corporation announced that Asuragen, Inc., a Bio-Techne brand, has launched a new kit to detect pathogenic variants in the CFTR gene.

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced executive appointments as the company prepares for future growth.

Compugen Ltd. a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced that management will present at the following investor conferences.

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today results from histology and biomarkers analyses in the ongoing Open-Label Part of the ARMOR Phase 3 study.